Radiological features of IDO1+/PDL1+ lung adenocarcinoma: A retrospective single-institution study

Kazuki Takada, Gouji Toyokawa, Tetsuzo Tagawa, Mototsugu Shimokawa, Kenichi Kohashi, Akira Haro, Atsushi Osoegawa, Yoshinao Oda, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

Aim: A combination of immune-checkpoint inhibitors that target the programmed cell death 1 (PD1)/programmed cell-death ligand 1 (PDL1) pathway and indoleamine 2,3-dioxygenase 1 (IDO1) is a promising treatment for non-small-cell lung cancer. Herein, we investigated clinical features of IDO1+/PDL1+ primary lung adenocarcinoma. Materials and Methods: IDO1 and PDL1 expression in 388 resected primary lung adenocarcinoma samples was evaluated using immunohistochemistry, and the radiological features of patients with IDO1+/PDL1+ lung adenocarcinoma were analyzed. Results: Of 388 specimens, 229 (59.0%) were IDO1+, 131 (33.8%) were PDL1+, and 109 (28.1%) were IDO1+/PDL1+. In multivariate analysis, vascular convergence and the absence of surrounding ground glass opacity were significantly associated with IDO1+/PDL1+ tumors. Fisher’s exact test showed high consolidation/tumor ratio was also significantly associated with IDO1+/PDL1+ tumors. Moreover, maximum standardized uptake in18F-fluorodeoxyglucose positron-emission tomography/computed tomography was significantly higher in patients with IDO1+/PDL1+ tumors than in those with IDO1 or PDL1 tumors. Conclusion: IDO1/PDL1 co-expression was significantly related to radiological invasiveness and malignancy in lung adenocarcinoma. This study may help select patients likely to benefit from combination therapy using immune-checkpoint inhibitors.

元の言語英語
ページ(範囲)5295-5303
ページ数9
ジャーナルAnticancer research
38
発行部数9
DOI
出版物ステータス出版済み - 9 2018

Fingerprint

CD274 Antigen
Indoleamine-Pyrrole 2,3,-Dioxygenase
Neoplasms
Adenocarcinoma of lung
Cell Death

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Radiological features of IDO1+/PDL1+ lung adenocarcinoma : A retrospective single-institution study. / Takada, Kazuki; Toyokawa, Gouji; Tagawa, Tetsuzo; Shimokawa, Mototsugu; Kohashi, Kenichi; Haro, Akira; Osoegawa, Atsushi; Oda, Yoshinao; Maehara, Yoshihiko.

:: Anticancer research, 巻 38, 番号 9, 09.2018, p. 5295-5303.

研究成果: ジャーナルへの寄稿記事

Takada, Kazuki ; Toyokawa, Gouji ; Tagawa, Tetsuzo ; Shimokawa, Mototsugu ; Kohashi, Kenichi ; Haro, Akira ; Osoegawa, Atsushi ; Oda, Yoshinao ; Maehara, Yoshihiko. / Radiological features of IDO1+/PDL1+ lung adenocarcinoma : A retrospective single-institution study. :: Anticancer research. 2018 ; 巻 38, 番号 9. pp. 5295-5303.
@article{9d3eb5b21ee6464f8859febbf0c2c02a,
title = "Radiological features of IDO1+/PDL1+ lung adenocarcinoma: A retrospective single-institution study",
abstract = "Aim: A combination of immune-checkpoint inhibitors that target the programmed cell death 1 (PD1)/programmed cell-death ligand 1 (PDL1) pathway and indoleamine 2,3-dioxygenase 1 (IDO1) is a promising treatment for non-small-cell lung cancer. Herein, we investigated clinical features of IDO1+/PDL1+ primary lung adenocarcinoma. Materials and Methods: IDO1 and PDL1 expression in 388 resected primary lung adenocarcinoma samples was evaluated using immunohistochemistry, and the radiological features of patients with IDO1+/PDL1+ lung adenocarcinoma were analyzed. Results: Of 388 specimens, 229 (59.0{\%}) were IDO1+, 131 (33.8{\%}) were PDL1+, and 109 (28.1{\%}) were IDO1+/PDL1+. In multivariate analysis, vascular convergence and the absence of surrounding ground glass opacity were significantly associated with IDO1+/PDL1+ tumors. Fisher’s exact test showed high consolidation/tumor ratio was also significantly associated with IDO1+/PDL1+ tumors. Moreover, maximum standardized uptake in18F-fluorodeoxyglucose positron-emission tomography/computed tomography was significantly higher in patients with IDO1+/PDL1+ tumors than in those with IDO1− or PDL1− tumors. Conclusion: IDO1/PDL1 co-expression was significantly related to radiological invasiveness and malignancy in lung adenocarcinoma. This study may help select patients likely to benefit from combination therapy using immune-checkpoint inhibitors.",
author = "Kazuki Takada and Gouji Toyokawa and Tetsuzo Tagawa and Mototsugu Shimokawa and Kenichi Kohashi and Akira Haro and Atsushi Osoegawa and Yoshinao Oda and Yoshihiko Maehara",
year = "2018",
month = "9",
doi = "10.21873/anticanres.12856",
language = "English",
volume = "38",
pages = "5295--5303",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "9",

}

TY - JOUR

T1 - Radiological features of IDO1+/PDL1+ lung adenocarcinoma

T2 - A retrospective single-institution study

AU - Takada, Kazuki

AU - Toyokawa, Gouji

AU - Tagawa, Tetsuzo

AU - Shimokawa, Mototsugu

AU - Kohashi, Kenichi

AU - Haro, Akira

AU - Osoegawa, Atsushi

AU - Oda, Yoshinao

AU - Maehara, Yoshihiko

PY - 2018/9

Y1 - 2018/9

N2 - Aim: A combination of immune-checkpoint inhibitors that target the programmed cell death 1 (PD1)/programmed cell-death ligand 1 (PDL1) pathway and indoleamine 2,3-dioxygenase 1 (IDO1) is a promising treatment for non-small-cell lung cancer. Herein, we investigated clinical features of IDO1+/PDL1+ primary lung adenocarcinoma. Materials and Methods: IDO1 and PDL1 expression in 388 resected primary lung adenocarcinoma samples was evaluated using immunohistochemistry, and the radiological features of patients with IDO1+/PDL1+ lung adenocarcinoma were analyzed. Results: Of 388 specimens, 229 (59.0%) were IDO1+, 131 (33.8%) were PDL1+, and 109 (28.1%) were IDO1+/PDL1+. In multivariate analysis, vascular convergence and the absence of surrounding ground glass opacity were significantly associated with IDO1+/PDL1+ tumors. Fisher’s exact test showed high consolidation/tumor ratio was also significantly associated with IDO1+/PDL1+ tumors. Moreover, maximum standardized uptake in18F-fluorodeoxyglucose positron-emission tomography/computed tomography was significantly higher in patients with IDO1+/PDL1+ tumors than in those with IDO1− or PDL1− tumors. Conclusion: IDO1/PDL1 co-expression was significantly related to radiological invasiveness and malignancy in lung adenocarcinoma. This study may help select patients likely to benefit from combination therapy using immune-checkpoint inhibitors.

AB - Aim: A combination of immune-checkpoint inhibitors that target the programmed cell death 1 (PD1)/programmed cell-death ligand 1 (PDL1) pathway and indoleamine 2,3-dioxygenase 1 (IDO1) is a promising treatment for non-small-cell lung cancer. Herein, we investigated clinical features of IDO1+/PDL1+ primary lung adenocarcinoma. Materials and Methods: IDO1 and PDL1 expression in 388 resected primary lung adenocarcinoma samples was evaluated using immunohistochemistry, and the radiological features of patients with IDO1+/PDL1+ lung adenocarcinoma were analyzed. Results: Of 388 specimens, 229 (59.0%) were IDO1+, 131 (33.8%) were PDL1+, and 109 (28.1%) were IDO1+/PDL1+. In multivariate analysis, vascular convergence and the absence of surrounding ground glass opacity were significantly associated with IDO1+/PDL1+ tumors. Fisher’s exact test showed high consolidation/tumor ratio was also significantly associated with IDO1+/PDL1+ tumors. Moreover, maximum standardized uptake in18F-fluorodeoxyglucose positron-emission tomography/computed tomography was significantly higher in patients with IDO1+/PDL1+ tumors than in those with IDO1− or PDL1− tumors. Conclusion: IDO1/PDL1 co-expression was significantly related to radiological invasiveness and malignancy in lung adenocarcinoma. This study may help select patients likely to benefit from combination therapy using immune-checkpoint inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85052997935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052997935&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12856

DO - 10.21873/anticanres.12856

M3 - Article

C2 - 30194181

AN - SCOPUS:85052997935

VL - 38

SP - 5295

EP - 5303

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 9

ER -